Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs.
This report contains market size and forecasts of Bispecific Antibody Therapeutic in global, including the following market information:
Global Bispecific Antibody Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Bispecific Antibody Therapeutic Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Bispecific Antibody Therapeutic companies in 2021 (%)
The global Bispecific Antibody Therapeutic market was valued at 3360.6 million in 2021 and is projected to reach US$ 15810 million by 2028, at a CAGR of 24.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Bearing An Fc Region Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bispecific Antibody Therapeutic include Creative-biolabs, PharmAbcine, Sorrento Therapeutics and Patheon, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bispecific Antibody Therapeutic manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bispecific Antibody Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bispecific Antibody Therapeutic Market Segment Percentages, by Type, 2021 (%)
Bearing An Fc Region
Lacking An Fc Region
Global Bispecific Antibody Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bispecific Antibody Therapeutic Market Segment Percentages, by Application, 2021 (%)
Osteology
Pulmonary
Respiratory Diseases
Oncology
Gene Therapy
Global Bispecific Antibody Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bispecific Antibody Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bispecific Antibody Therapeutic revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Bispecific Antibody Therapeutic revenues share in global market, 2021 (%)
Key companies Bispecific Antibody Therapeutic sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Bispecific Antibody Therapeutic sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Creative-biolabs
PharmAbcine
Sorrento Therapeutics
Patheon